Palomar Medical Technologies, Inc. (PMTI)

[Penny Roger$]

~ Thurs-Fri $PMTI ~ Earnings posted, pending or coming soon! In Charts and Links Below!

~ $PMTI ~ Earnings expected on Thursday *
Want more like this? Search Keyword: MACMONEY >>> http://tinyurl.com/MACMONEY <<<
One or more of many earnings sites has alerted this security has or will be posting earnings on or around the day of this message.








http://stockcharts.com/h-sc/ui?s=PMTI&p=D&b=3&g=0&id=p88783918276&a=237480049




http://stockcharts.com/h-sc/ui?s=PMTI&p=W&b=3&g=0&id=p54550695994



~ Google Finance: http://www.google.com/finance?q=PMTI
~ Google Fin Options: hhttp://www.google.com/finance/option_chain?q=PMTI#
~ Yahoo! Finance ~ Stats: http://finance.yahoo.com/q/ks?s=PMTI+Key+Statistics
~ Yahoo! Finance ~ Profile: http://finance.yahoo.com/q/pr?s=PMTI
Finviz: http://finviz.com/quote.ashx?t=PMTI
~ BusyStock: http://busystock.com/i.php?s=PMTI&v=2


<<<<<< http://www.earningswhispers.com/stocks.asp?symbol=PMTI >>>>>>



http://investorshub.advfn.com/boards/post_prvt.aspx?user=251916

*If the earnings date is in error please ignore error. I do my best.

[mugur]

Finally, very good news, but it looks like the price does not reflect it

[mlkrborn]

Palomar Medical and Syneron (ELOS) announce settlement of patent infringement lawsuits (PMTI) 8.40 : Under this Agreement, Candela and Syneron will pay co $31 mln by September 19, 2011. In addition, co will receive a royalty-free license to certain Candela patents. Under the second Agreement, co will grant to Syneron and affiliates a non-exclusive, royalty bearing, license in the United States to U.S. Patent Nos. 5,735,844 and 5,595,568 for consumer home-use lamp-based hair removal products. Syneron will pay co on sales in the United States a 5.0% royalty up to an undisclosed amount of cumulative sales, then 6.5% up to the next undisclosed amount of cumulative sales, and 7.5% on all cumulative sales thereafter. In addition, co will receive a royalty-free license to certain Syneron and Candela patents.

[mugur]

$20 is the big barrier to cross

[nlightn]

Palomar Medical Reports Financial Results for Fourth Quarter and Fiscal Year 2010

Interest in First of Its Kind Home-Use PaloVia(TM) Skin Renewing Laser(TM) for the Treatment of Fine Lines and Wrinkles Around the Eyes Exceeds Expectations

February 10, 2011, 8:00 am EST

BURLINGTON, Mass.(GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the fourth quarter and year ended December 31, 2010. Revenues for the quarter ended December 31, 2010 increased to $16.4 million, as compared to $16.3 million reported in the fourth quarter of 2009. Product and service revenues were $14.3 million, a 2 percent increase over the $14.0 million reported in the fourth quarter of 2009. Fourth quarter gross margin from product and service revenues was 61 percent, which was consistent with the fourth quarter of 2009. Loss before income taxes for the fourth quarter ended December 31, 2010 was $2.4 million, which included a $0.6 million patent litigation expense and a $1.0 million non-cash stock-based compensation expense. Loss before income taxes for the fourth quarter ended December 31, 2009 was $3.3 million, which included a $0.2 million patent litigation expense and a $4.5 million non-cash stock-based compensation expense. Approximately $3.5 million of the fourth quarter 2009 non-cash stock-based compensation expense was a one-time expense related to the granting of restricted stock awards. The Company reported net loss of $2.6 million, or $0.14 per share for the fourth quarter of 2010 and $8.5 million for the fourth quarter of 2009. The balance sheet continues to be strong with $103.0 million in cash, cash equivalents, short-term investments, and marketable securities with no borrowings.

Revenues for the year ended December 31, 2010 increased to $63.7 million, as compared to $60.6 million reported in 2009. Product and service revenues were $53.5 million, a 10 percent increase over the $48.8 million reported in 2009. For the year ended December 31, 2010, gross margin from product and service revenues was 62 percent compared to 58 percent reported in 2009. Loss before income taxes for the year ended December 31, 2010 was $8.5 million, which included a $3.5 million patent litigation expense and a $3.8 million non-cash stock-based compensation expense. Loss before income taxes for the year ended December 31, 2009 was $6.0 million, which included a $0.8 million patent litigation expense and a $7.1 million non-cash stock-based compensation expense. The Company reported net loss of $8.8 million, or $0.47 per share for the year ended December 31, 2010, and a net loss of $10.5 million, or $0.58 per share for the year ended December 31, 2009.

Chief Executive Officer Joseph P. Caruso commented, "We are pleased with the growth in product revenue this year as compared to last year. Prices remained stable and gross margins are in excess of 60%. We have seen an increase in interest for our products and are working toward a stronger presence internationally. We believe our diversified portfolio of products and strong balance sheet perfectly positions the company for future growth as the economy begins to strengthen."

Mr. Caruso continued, "In late December, we launched our first consumer product, the PaloVia Skin Renewing Laser. The initial interest in this product and new category is much higher than we anticipated. Our public relations efforts are paying off and exposure for our product and company continue to grow. The initial orders of the PaloVia Skin Renewing Laser exceeded our projections and we are increasing our production capabilities to meet demand. The consumer products category represents a new and exciting opportunity for us to engage the consumer directly and introduce our technology to the masses. We believe direct access to the consumer provides us with a very large opportunity to establish Palomar in the multi-billion dollar beauty market. It will also enhance our position in the professional physician's market with a complementary product offering and help drive new patients to doctor's offices."

Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM Eastern Time. Management will discuss financial results and strategic matters. If you would like to participate, please call [phone] or listen to the webcast in the About Palomar/Investors section of the Company's website at www.palomarmedical.com. A webcast replay will also be available.

http://finance.yahoo.com/news/Palomar-Medical-Reports-pz-3573479418.html?x=0&.v=1

[nlightn]

Palomar Medical Presents New Acne Product at the American Academy of Dermatology Annual Meeting
February 4, 2011, 10:51 am EST

BURLINGTON, Mass., Feb. 4, 2011 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, announced today the launch of the Acleara(TM) acne clearing system at the 69th Annual Meeting of the American Academy of Dermatology (AAD) in New Orleans, Louisiana, from February 5th through February 7th.

The Acleara acne clearing system uses broad band light and suction to treat mild to moderate acne including acne vulgaris, comedonal and pustular acne. With the Acleara system, practitioners can treat a full face in less than 15 minutes with no numbing or cooling gels and no anesthetic costs.

Acleara provides deep cleaning of pores by extracting accumulated sebaceous material, and provides targeted heating of sebaceous glands. The light activates endogenous porphyrins to destroy P. acnes and reduces sebum production through photodynamic action.

According to Dr. Robert Berger, a practicing Dermatologist from Waldorf, MD and an Associate Professor of Dermatology from Johns Hopkins School of Medicine, regarding the Acleara system, "I have performed over 15,000 treatments over 5 years using a number of different technologies to treat acne. The Acleara system has proven more effective, less painful and it delivers superior results as compared to any previous technologies I have tried in treating active acne."

Joseph P. Caruso, Chief Executive Officer, commented, "We are very excited about this product launch. It is a fantastic addition to our robust family of products and allows us to address the enormous acne market. The American Academy of Dermatology reports that Acne vulgaris is the most common skin condition in the United States. Up to 50 million Americans have acne and 85 percent of all U.S. teenagers have acne. The Acleara system offers physicians advanced technology to both deep clean and treat the skin."

Mr. Caruso continued, "Many who suffer from acne cannot tolerate or do not want to have their acne treated by drugs. The Acleara system is an excellent alternative for consumers and physicians alike."

Attendees at the AAD Annual Meeting in New Orleans can learn about the Acleara acne clearing system at Palomar's exhibition hall booth, #811.

About Palomar Medical Technologies Inc: Palomar designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women's and men's skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry's technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter ("OTC") clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). This OTC clearance allows Palomar to market and sell the PaloVia(TM) Skin Renewing Laser(TM) directly to consumers without a prescription.

For more information on Palomar and its products, visit Palomar's website at palomarmedical.com or palovia.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of palomarmedical.com.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2009 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

Kerry McAnistan
Investor Relations Assistant
Palomar Medical Technologies, Inc.
781-993-2411
[e-mail]

http://finance.yahoo.com/news/Palomar-Medical-Presents-New-pz-913693199.html?x=0&.v=1

[nlightn]

Palomar Medical Technologies to Host Fourth Quarter and Year End 2010 Financial Results Conference Call and Webcast on February 10, 2011
PR Newswire
January 27, 2011, 10:00 am EST

BURLINGTON, Mass., Jan. 27, 2011 /PRNewswire/ -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, will hold its quarterly conference call of its 2010 fourth quarter and year-end financial results on Thursday, February 10, 2011 at 11:30 AM Eastern Time. If you would like to participate, please call [phone] at 11:20 AM Eastern Time on that day.

A live webcast of Palomar's conference call will be available in the Investor Relations' section of the Company's web site www.palomarmedical.com. The online archive will be available one hour after the call and continue through Thursday, February 17, 2011.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations' section of the website.

About Palomar Medical Technologies Inc: Palomar designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women's and men's skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry's technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) over-the-counter ("OTC") clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). OTC clearance allows these products to be marketed and sold directly to consumers without a prescription.

Contacts:


Kerry McAnistan
Investor Relations Assistant
Palomar Medical Technologies, Inc.
781-993-2411
[e-mail]

http://finance.yahoo.com/news/Palomar-Medical-Technologies-prnews-2515796868.html?x=0&.v=1

[nlightn]

President And CEO Interview: Palomar Medical Technologies, Inc. (PMTI) - Joseph P. Caruso
January 26, 2011, 4:09 pm EST

In the following brief excerpt from the Medical Devices Report, interviewees discuss the outlook for the sector and for investors.

Joseph P. Caruso has held senior management positions at Palomar Medical Technologies, Inc., since 1992, the year after its founding, and he has been one of the company's Directors since October 2001. In his most recent tenure as President and CEO, Mr. Caruso has focused the company on light-based aesthetic treatments. Within and outside of the organization, Mr. Caruso has championed the strategy of cascading laser technology from professional settings, such as doctors' offices, to at-home use.

TWST: Please start with a short introduction to Palomar Medical's operations.

Mr. Caruso: We are a company that develops, sells and markets professional light-based aesthetic devices, and recently we've expanded that into the consumer market as well.

TWST: Would you comment on your platform and the total number of procedures you have built into that platform?

Mr. Caruso: We sell devices to the professional market, including dermatologists, plastic surgeons and other physicians around the world. We have thousands of systems installed, and those thousands of systems are used in many different treatments around the world.

TWST: Do you sell one workstation for all of these applications?

Mr. Caruso: We sell a number of different products. It is a base system that runs a number of handpiece applicators that all do different treatments, but they're all focused on aesthetic light-based procedures.

TWST: What are the more popular applications?

Mr. Caruso: The most popular application is light-based hair removal. Palomar (PMTI)was the first company to receive FDA clearance for a high-powered light-based hair removal device in 1996, and we also control the key patents for light-based hair removal. That's the most popular application of light-based aesthetic treatment today. In addition to that, we also control a fundamental patent in fractional technology for our devices.

And those types of applications include things like skin resurfacing, skin rejuvenation, wrinkle treatments, skin tightening. These are applications that are all grouped into facial rejuvenation or skin rejuvenation treatments, and we sell a number of different products in that area as well. We also sell some specialty laser devices and applications that include laser lipolysis, so using a laser, a light source to melt the fat before that fat is removed - that's a minimally invasive procedure - as well as some other procedures, including tattoo removal, leg vein treatment and so forth.

TWST: Aside from hair removal, how often does a patient have to return for a lasting solution?

Mr. Caruso: It depends on the application and the treatment. Some applications of our technology are one-time, such as leg vein treatments for instance, or rosacea; some of those can be done in one treatment. Many of the treatments are done in multiple treatment protocols, including tattoo removal, non-ablative and ablative skin rejuvenation, hair removal, as you mentioned, and some others. So most of the procedures are multiple applications of the technology anywhere from two to as many as eight different procedures in a course of treatment, and some of the treatments can be done in one treatment.

TWST: What is the cost range for a typical noninvasive aesthetic laser treatment?

Mr. Caruso: Depending on where it's done and the type of treatment, treatment's pricing can range anywhere from as low as $50 a treatment to as much as $1,000 a treatment. It's a very wide range of pricing.

TWST: Are these units sold directly to the physician? Is that your basic business model?

Mr. Caruso: The basic business model is we research, develop and manufacture the equipment. We then sell the devices directly or through distributors to the physicians for use on their patients.

TWST: What's Palomar's growth rate and how would you compare it with the overall marketplace?

Mr. Caruso: Our growth rate was very substantial and dramatic from 2001 to 2007. When the worldwide economic recession hit in 2008-2009, we saw a big drop-off in our business. But over the last four quarters or so, we've seen some growth come back into the market and into the business.

http://finance.yahoo.com/news/President-And-CEO-Interview-twst-2969085944.html?x=0&.v=1

[nlightn]

Palomar to Host PaloVia Skin Renewing Laser Analyst and Investor Meeting in NYC
GLOBE NEWSWIRE
Burlington, Mass.
Jan. 6, 2011

Palomar Medical Technologies, Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, will host an analyst and investor meeting to discuss its launch plans for the first FDA-cleared, at-home laser clinically proven to reduce fine lines and wrinkles around the eyes - the PaloVia(TM) Skin Renewing Laser(TM).

The meeting will be held today from 10AM to 12PM in New York City at the Nasdaq MarketSite, 4 Times Square, second floor Press Conference Room. Presenters from Palomar will be Joseph Caruso, Chief Executive Officer; Paul Weiner, Chief Financial Officer; Nancy Teumer, Global Marketing Director Consumer Products; David Montgomery, Consumer Products Sales Director; and Richard Bankowski, Field Clinical Director and QVC Spokesperson.

Also presenting will be Palomar's PaloVia Expert Panel member, Dr. Robert Weiss, Director, Maryland Laser, Skin & Vein Institute. Attendees are asked to arrive early to allow adequate time for security checks. For analysts and investors that are not able to attend the PaloVia launch meeting in New York City, the meeting will also be accessible via webcast in the About Palomar/Investors section of Palomar's website at palomarmedical.com.

http://finance.yahoo.com/news/Palomar-to-Host-PaloVia-Skin-pz-4086552490.html?x=0&.v=1

[nlightn]

Palomar Offers New Skin Rejuvenation Platform and Announces the First FDA Clearance for Combination Fractional Resurfacing
BURLINGTON, Mass.
GLOBE NEWSWIRE
Jan. 18, 2011 (

Palomar Medical Technologies, Inc., a leading researcher and developer of lasers and pulsed-light systems for aesthetic treatments, is pleased to announce that the Artisan(TM) Aesthetic System is now being shipped. The Artisan provides a combined fractional ablative and fractional non-ablative laser skin resurfacing treatment -- the first approach of this kind to receive clearance by the United States Food and Drug Administration.

The Artisan Aesthetic System includes a 1540 nm or 1440 nm non-ablative fractional laser and a 2940 nm ablative fractional laser for skin resurfacing and a MaxG(TM) optimized light handpiece for the treatment of pigmented and vascular lesions. Palomar's new FDA clearance covers the combination use of both the non-ablative and ablative fractional lasers during the same treatment session. Palomar believes that this specific collection of skin resurfacing and photofacial technologies allows practitioners to tailor a complete skin rejuvenation regimen for each individual client.

"Artisan combines the best of our non-ablative and ablative fractional laser technologies with our optimized light technology. This combination of technologies can be used to improve skin tone and texture, along with specific laser treatments for wrinkles, scars, and stretch marks. Practitioners now have the multiple technologies they need for an overall best-in-class treatment depending on each individual client's age, skin condition, and downtime preference," said Joseph P. Caruso, Palomar's President and Chief Executive Officer.

Palomar's unique combination ablative and non-ablative fractional treatment provides a direct benefit to clients. Arielle Kauvar, MD, director of New York Laser and Skin Care, said, "What is special about Artisan is that I customize just the right amount of ablative or non-ablative fractional treatment to fit each patient's needs for facial rejuvenation, as each patient has different preferences for speed of treatment, downtime, and the number of treatments they're willing to undergo. With Artisan, I can also treat the many patients who have scars and stretch marks." In 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional laser.

"Our goal is to ensure our customers can access our leading technology with packaging and pricing programs that best fit their financial needs. No other aesthetic system provides so many superior technologies for facial rejuvenation in one package, cost-effectively," said Mr. Caruso. "Palomar continues to offer product configurations that fit into today's economy. Aesthetic providers now have the ability to match our technology to fit not only their clinical needs, but their financial constraints as well," continued Paul S. Weiner, Senior Vice-President, Chief Financial Officer, and Treasurer.

To learn more about the Artisan Aesthetic System, and Palomar's unique FDA clearance for a combination fractional resurfacing treatments, please visit http://www.palomarmedical.com.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for aesthetic treatments.

Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology.

As a pioneer of fractional technology, Palomar is an owner of fundamental intellectual property in this area. In December 2009, Palomar received the first FDA clearance for the treatment of stretch marks using a fractional non-ablative laser. In September 2010, Palomar received the first FDA clearance for a fractional ablative and fractional non-ablative combination treatment.

In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription.

There are now millions of light-based aesthetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the aesthetic market and other surgical applications.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com.

Contact:

Branden Morris
Palomar Medical Technologies, Inc.
[phone]
[e-mail]

http://finance.yahoo.com/news/Palomar-Offers-New-Skin-pz-2289470164.html?x=0&.v=1

[nlightn]

PMTI [PIVOT POINTS]...had a nice big buy at market close...

4,967 shares at $14.73...

nice momentum for market open tomorrow.

lets hope it can begin a new leg of $15 and hold and move.

R1 is at $15.01...break it we're off to the races

PIVOT POINTS

R4 16.41
midpoint 16.12
R3 15.83
midpoint 15.54
R2 15.25
midpoint 15.13
R1 15.01
midpoint 14.84
PP 14.67
midpoint 14.55
S1 14.43
midpoint 14.26
S2 14.09
midpoint 13.80
S3 13.51
midpoint 13.22
S4

[nlightn]

actually still holding the calls. i think we have a little bit more to go.

of course i have to time expiration the chart looks like we haev some more upward momentum.

[mugur]

Nice, you can sell @ $1.20 and have $1 /contract profit!

[nlightn]

oh yea...i've had them for a while in anticipation of good news on their product launch....it paid off so far. in @ .20. now @ 1.00. still holding them.

works for me ;^)

[mugur]

Happy New Year! QVC is BIG! Did you get any of those FEB 15 calls?

[nlightn]

PMTI's PaloVia At-home Laser Treatment on QVC

(QVC presentation link below story)

PaloVia Skin Renewing Laser for Wrinkle Reduction Launches on QVC
Lisa Schweitzer
Dec 27th 2010



We've got big news on the crow's feet front!

The PaloVia Skin Renewing Laser launches today on QVC and it's the only FDA-cleared, at-home laser clinically proven to reduce fine lines and wrinkles around the eyes.

You've probably heard your dermatologist say "the only thing we can do for your crow's feet is a series of laser treatments." Well, now you can do it yourself in the privacy of your bathroom and at a fraction of the price.

The PaloVia device is about the size of a large remote control and after 30 days of use, clinical studies administered by dermatologists and plastic surgeons found a noticeable reduction in wrinkles in 92 percent of participants.

The device generates short pulses of micro-fine laser light that penetrate your skin's sub-layers where wrinkles form, treating the aging support structure. Then the body's natural healing process sweeps away older, damaged tissue and rebuilds it with new collagen and elastin, stimulating younger-looking and smoother skin.

Each treatment session takes about three to four minutes and you only have to use it once a day. After one month, use it twice a week to help maintain your results.

Afraid you'll screw up and accidentally shoot the laser in your eye? The experts at Palomar (the company that created PaloVia) have you covered -- there's a built-in sensor that works with the Pre-Treatment Gel to verify complete skin contact, plus audio and visual cues and an automatic shut-off help to prevent overuse.

PaloVia Skin Renewing Laser retails for $499 and is available exclusively through QVC and palovia.com starting December 27. Distribution will expand in January to include Nordstrom.

http://www.stylelist.com/2010/12/27/palovia-skin-renewing-laser-qvc/

(click on Videos)
http://www.qvc.com/qic/qvcapp.aspx/view.2/app.detail/params.item.A212768.desc.PaloVia-AtHome-Skin-Renewing-Laser-Pre-Treatment-Gels.CM_SCID.coll

[nlightn]

PMTI Feb '11 $15 call options getting action...

core price of PMTI up +.44 and is attempting to start anew leg in to the $14 territory.

Time 7 Sales
Feb '11 $15 Call Options

12/27/2010 09:56:03 100 0.65
12/27/2010 11:30:15 PSE 10 0.75


PMTI 6Month RSI, MACD, ADX

[nlightn]

PMTI breaking the $14 level...looking to grow another leg..with strength lets hope.

[nlightn]

Break Out...

PMTI busted through the cup & handle at 13.58 this a.m.

big time option buying on the Feb 2011 $15 calls.

[nlightn]

this is the other revenue producing potential for PMTI...

Palomar Reopens Infringement Lawsuit Against Candela and Syneron
January 6, 2010

Citing recent victories at the U.S. Patent and Trademark Office and the European Patent Office, Palomar Medical Technologies resumes its legal fight against Candela and Syneron, aiming for its day in court this year.


Palomar Medical Technologies Inc. (NSDQ:PMTI) has a wedding present for Candela Corp. (NSDQ:CLZR) and Syneron Inc. (NSDQ:ELOS): Another patent infringement lawsuit.

The Burlington, Mass.-based cosmetic laser device maker said it's resuming its patent infringement lawsuit against newly united Candela and Syneron, which officially closed their merger on Tuesday.

Palomar said it received permission from the court to re-file its infringement lawsuit over a "Hair Removal Using Optical Pulses" patent. The courts decision follows a pair of decisions in the U.S. Patent and Trademark Office and the European Patent Office. Both entities upheld the bulk of device maker's patents as "novel and inventive" over its competitors'. Palomar filed the original lawsuit in the U.S. District Court for Massachusetts.

Palomar first made its intentions to re-start the case clear in a July 30, 2009, earnings release, in which it revealed that it was filing a motion to restart the case.

In a prepared release, Patricia Davis, Palomar's general counsel, said the next step was to set a day in court, which she hoped would come some time in the next calendar year.

"Our case against Candela is very far along and we will request a trial date as soon as possible," Davis said.

The case dates back to a pair of patents Palomar licensed from Mass. General Hospital back in 1995 for light-based hair removal. Palomar says Candela and Syneron willfully copied the company's technology, CEO Joseph Caruso said in a statement.

"After establishing light-based hair removal as a viable treatment option, many competitors began to use our technology. Several properly took licenses while others opted not to at their own risk. Unauthorized taking of technology is what the patent system is designed to prevent. We intend to continue our aggressive patent enforcement strategy both to protect our own investment in research and market development as well as the investment of our licensees."

http://www.massdevice.com/news/palomar-reopens-infringement-lawsuit-against-candela-and-syneron

[nlightn]

Golden Cross..it already happened...

50MA crossed the 100MA the third week of Nov and the 50MA crossed the 200MA the fourth week if Nov as the chart displays.

[nlightn]

Are Shorts Watching Palomar Medical Technologies?
Seth Jayson
December 16, 2010

There's no foolproof way to know the future for Palomar Medical Technologies (Nasdaq: PMTI) or any other company. However, certain clues may help you see potential stumbles before they happen -- and before your stock craters as a result. Rest assured: Even if you're not monitoring these metrics, short-sellers are.

A Cloudy Crystal Ball

I often use accounts receivable (AR) and days sales outstanding (DSO) to judge a company's current health and future prospects. It's an important step in separating the pretenders from the market's best stocks. Alone, AR -- the amount of money owed the company -- and DSO -- days worth of sales owed to the company -- don't tell you much. However, by considering the trends in AR and DSO, you can sometimes get a window onto the future.

Sometimes, problems with AR or DSO simply indicate a change in the business (like an acquisition), or lax collections. However, AR that grows more quickly than revenue, or ballooning DSO, can also suggest a desperate company that's trying to boost sales by giving its customers overly generous payment terms. Alternately, it can indicate that the company sprinted to book a load of sales at the end of the quarter, like used-car dealers on the 29th of the month. (Sometimes, companies do both.)

Why might an upstanding firm like Palomar Medical Technologies do this? For the same reason any other company might: to make the numbers. Investors don't like revenue shortfalls, and employees don't like reporting them to their superiors.

Is Palomar Medical Technologies sending any potential warning signs? Take a look at the chart below, which plots revenue growth against AR growth, and DSO:




Source: Capital IQ, a division of Standard & Poor's. Data is current as of last fully-reported fiscal quarter. FQ = fiscal quarter.

The standard way to calculate DSO uses average accounts receivable. I prefer to look at end-of-quarter (EOQ) receivables, but I've plotted both above.

Watching The Trends

When that red line (AR growth) crosses above the green line (revenue growth), I know I need to consult the filings. Similarly, a spike in the blue bars (DSO) indicates a trend worth worrying about. As another reality check, it's reasonable to consider what a normal DSO figure might look like in this space.

Company LFQ Revenue DSO
Palomar Medical Technologies $16 29
Solta Medical (Nasdaq: SLTM) $25 40
Cynosure (Nasdaq: CYNO) $19 52
Syneron Medical (Nasdaq: ELOS) $44 88

Source: Capital IQ, a division of Standard & Poor's. DSO calculated from average AR. Data is current as of last fully-reported fiscal quarter. LFQ = last fiscal quarter. Dollar figures in millions.

Differences in business models can generate variations in DSO, so don't consider this the final word -- just a way to add some context to the numbers. But let's get back to our original question: Will Palomar Medical Technologies miss its numbers in the next quarter or two?

The numbers don't paint a clear picture. For the last fully reported fiscal quarter, Palomar Medical Technologies's year-over-year revenue grew 8.4%, and its AR dropped 8.4%. That looks OK. End-of-quarter DSO decreased 15.5% from the prior-year quarter. But it was up 26.8% versus the prior quarter. That demands a good explanation. Still, I'm no fortuneteller, and these are just numbers. Investors putting their money on the line always need to dig into the filings for the root causes and draw their own conclusions.

What now?

I use this kind of analysis to figure out which investments I need to watch more closely as I hunt the market's best returns. However, some investors actively seek out companies on the wrong side of AR trends in order to sell them short, profiting when they eventually fall. Which way would you play this one? Let us know in the comments below, or keep up with the stocks mentioned in this article by tracking them in our free watchlist service, My Watchlist.


http://www.fool.com/investing/general/2010/12/16/are-shorts-watching-palomar-medical-technologies.aspx

[mugur]

Let's see if the Golden Cross will happen:the 50 MA over 200 MA

[nlightn]

Introducing the PaloVia(TM) Skin Renewing Laser(TM) From Palomar Medical Technologies, Inc.
GlobeNewswire
Dec. 15, 2010



Palomar Medical Technologies, Inc. (PMTI) , a leading researcher and developer of light-based systems for cosmetic treatments, today announced the launch of the first FDA-cleared, at-home laser clinically proven to reduce fine lines and wrinkles around the eyes -- the PaloVia Skin Renewing Laser. The First FDA-Cleared, At-Home Laser Clinically Proven to Reduce Fine Lines and Wrinkles Around the Eyes


Palomar will host an analyst and investor meeting to discuss its launch plans in New York City on January 6, 2011 from 10AM to 12PM at the Nasdaq MarketSite, 4 Times Square, second floor Press Conference Room. Attendees from Palomar will be Joseph Caruso, Chief Executive Officer; Paul Weiner, Chief Financial Officer; Nancy Teumer, Global Marketing Director Consumer Products; David Montgomery, Consumer Products Sales Director; and Richard Bankowski, Field Clinical Director and QVC Spokesperson. Also in attendance will be one of Palomar's PaloVia Expert Panel Members Dr. Robert Weiss, Director, Maryland Laser, Skin & Vein Institute. For analysts and investors that are not able to attend the PaloVia launch meeting in New York City, the meeting will also be accessible via webcast in the About Palomar/Investors section of Palomar's website at palomarmedical.com.

As an industry leader and pioneer in the science of using lasers and light to improve personal appearance, Palomar's patented fractional technology has been proven by dermatologists worldwide for more than a decade. Now, for the first time ever, this same technology has been adapted and perfected for use at home, delivering a visible improvement in fine lines and wrinkles. In a clinical study, a panel of doctors specializing in dermatology and plastic surgery saw a noticeable reduction in wrinkles in 92% of participants after one month of daily treatments.

"The PaloVia Skin Renewing Laser is the result of years of comprehensive research and development and the beginning of what we expect will be a new era in delivering convenient light-based technology treatments for people to use in the privacy and comfort of their own homes," said Joseph P. Caruso, Chief Executive Officer, Palomar Medical Technologies, Inc. "We are thrilled to offer our first-to-market, FDA-cleared laser to consumers who can now experience the clinically proven benefits of laser skin treatments, on their own terms at home."

Unlike lotions and creams, which are most effective on the skin's outer layer, the PaloVia laser also works below the surface where wrinkles form. It generates pulses of micro-fine laser light that reach deeply into the skin's sub-layers, treating the skin's aging support structure. Then the body's natural healing process sweeps away the older, damaged tissue and rebuilds it with fresh, new collagen and elastin -- the crucial building blocks of smooth, youthful skin.

"The PaloVia Skin Renewing Laser uses a technology that works from a company I've trusted for years to help me deliver the best results for my patients," said Dr. Robert Weiss, Director, Maryland Laser, Skin & Vein Institute. "For consumers who want to treat fine lines and wrinkles around their eyes, I strongly recommend the PaloVia laser as a worthwhile addition to a proactive skincare regimen."

The PaloVia laser is available now for advanced sale though QVC online and will debut on the QVC television program PM Style with Lisa Robertson on December 27 at 7:00PM. The palovia.com website will also go live on December 27 and the PaloVia laser will start shipping to consumers in the middle of January. Distribution will be expanded in January to include Nordstrom, with physicians' offices and additional retailers coming on board throughout the first few months of 2011. The product has a suggested retail price of $499 and comes with a 60-day money back guarantee.

About Palomar Medical Technologies, Inc.: Palomar Medical Technologies (PMTI) designs, produces and sells the most advanced cosmetic lasers and intense pulsed light (IPL) systems to dramatically improve the appearance of women's and men's skin. For over 15 years, Palomar has pioneered the science of using lasers and light to improve appearances. As the industry's technology leader, Palomar has invested in creating cosmetic laser and IPL systems that put real value in the hands of physicians and other professionals to benefit consumers. Thousands of physicians worldwide trust and depend on Palomar technology to not only introduce new aesthetic treatments such as advanced laser hair removal, laser liposuction, skin resurfacing, acne, laser treatments for scars, wrinkle treatment, stretch marks (striae), and photofacials for pigmented and vascular lesions, but to also make them robust, faster, more powerful, and more comfortable for those being treated. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of fine lines and wrinkles around the eyes (periorbital wrinkles). OTC clearance allows these products to be marketed and sold directly to consumers without a prescription.

For more information on Palomar and its professional products, visit the company's website at palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the About Palomar/Investors section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets and the development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2009 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

This news release was distributed by GlobeNewswire, www.globenewswire.com

SOURCE: Palomar Medical Technologies, Inc.

CONTACT: Palomar Medical Technologies, Inc.
Investor/Financial Contact:
Kerry McAnistan, Investor Relations Assistant
781-993-2411
[e-mail]
Bratskeir & Company
Consumer Media Contact:
Lauren Glicken O'Leary
[e-mail]
Rebecca Levitt
[e-mail]
212-679-2233

(C) Copyright 2010 GlobeNewswire, Inc. All rights reserved.

[nlightn]

Investors Bid Up Shares of Palomar Medical Technologies, Up 2.8% (PMTI)

Dec 15, 2010 (SmarTrend(R) Market Surveillance via COMTEX) -- Palomar Medical Technologies (PMTI) is one of today's notable stocks on the rise, up 2.8% to $13.21. The S&P is currently trading fractionally higher to 1,242 and the Dow Jones Industrial Average is trading 0.3% higher to 11,515.

Palomar Medical Technologies is in SmarTrend's Medical Instruments industry and this industry is currently in an Uptrend according to our research. We are monitoring many other stocks on the move within this industry.

In the last five trading sessions, the 50-day MA has climbed 2.3% while the 200-day MA has risen 0.88%.

In the past 52 weeks, shares of Palomar Medical Technologies have traded between a low of $8.56 and a high of $13.48 and are now at $13.21, which is 54% above that low price.

SmarTrend currently has shares of Palomar Medical Technologies in an Uptrend and issued the Uptrend alert on September 28, 2010 at $10.30. The stock has risen 24.7% since the Uptrend alert was issued.

[nlightn]

Palomar Medical Technologies: The Trend Continues Higher (PMTI)

Dec 15, 2010 (SmarTrend(R) Spotlight via COMTEX) -- SmarTrend identified an Uptrend for Palomar Medical Technologies (PMTI) on September 28, 2010 at $10.30. In approximately 3 months, Palomar Medical Technologies has returned 24.8% as of today's recent price of $12.86.

In the past 52 weeks, shares of Palomar Medical Technologies have traded between a low of $8.56 and a high of $13.48 and are now at $12.86, which is 50% above that low price.

Palomar Medical Technologies is currently above its 50-day moving average of $11.48 and above its 200-day moving average of $10.92. Look for these moving averages to climb to confirm the company's upward momentum.

In the last five trading sessions, the 50-day MA has climbed 2.34% while the 200-day MA has risen 0.9%.

SmarTrend will continue to scan these moving averages and a number of other proprietary indicators for any shifts in the trajectory of Palomar Medical Technologies shares.

[mugur]

You were right on the money! that's the news that was pushing the price up.
You should get a nice bump on those options.

[nlightn]

Palomar and P&G Amend License Agreement to Support Successful Product Launch
GlobeNewsWire
Dec. 10, 2010

BURLINGTON, Mass., Dec. 9, 2010 (GLOBE NEWSWIRE) -- Palomar Medical Technologies, Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, today announced that it has entered into an amendment to its non-exclusive License Agreement executed February 29, 2008 (retroactively effective as of February 14, 2003) with The Procter & Gamble Company (NYSE:PG - News). The amendment provides additional funding from each company to meet the common goal of a successful product launch. The amendment does not change the scope of P&G's non-exclusive license to Palomar's broad patent portfolio as well as its non-exclusive license to the extensive technology developed by Palomar prior to February 28, 2008 for home-use light-based hair removal devices for women.

Under the amended License Agreement, P&G and Palomar have agreed to reduce pre-commercial launch calendar quarterly payments from $1.25 million to $1 million for the calendar quarter ending December 31, 2010 and thereafter to $2 million per year for an agreed period, after which the payments return to $1.25 million per calendar quarter if no product has been launched. P&G will apply the savings, together with agreed minimum overall program funding, to accelerating product readiness and commercialization while Palomar will be paid an increased percentage of sales after commercial launch.

P&G's Vice President of New Business Creation Jennifer Dauer said, "We have been actively working on development of this product and are pleased with our progress to date. This amendment better balances short and long term financial compensation to enable our mutual objective of successfully getting this technology to market."

Commenting on this development, Palomar Chief Executive Officer Joseph P. Caruso said, "Together the companies have each agreed to invest more to put this product in consumers' hands as early as possible. We are trading some of our fixed short-term pre-commercial launch calendar quarterly payments for an increase in sales related payments post launch that we believe will provide us greater benefit in the long run."

For more information, please see the Amendment filed as Exhibit 10.1 to a Current Report on Form 8-K filed today and the non-exclusive License Agreement filed as Exhibit 10.1 to a Current Report on Form 8-K filed March 3, 2008.

About Palomar Medical Technologies Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows these products to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the About Palomar/Investors section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2009 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contact:

Palomar Medical Technologies, Inc.
Kerry McAnistan, Investor Relations Assistant
781-993-2411
[e-mail]

http://finance.yahoo.com/news/Palomar-and-PG-Amend-License-pz-2008654336.html?x=0

[mugur]

Nice observation, let's see if we get a PR explaining the volume

[nlightn]

great VOLUME DAY...385,634. now we need for this volume to sustain and get to a closing price of $13.31.

on a T/A basis...looks like a cup&handle is forming channeling out at this current level to from the handle. nice bullish sign.

that volume was for a reason, what the reason actually is i don't know. but this was three times the volume that usually occurs. maybe some insiders stacking their share pile.

time will tell.

[nlightn]

i've been in the Feb $15calls since .20.

it's not that i wouldn't consider March options..at this point there is no market for them. i assume if you call your broker and state you want to buy-to-open i'm fairly sure they would open them up for trading.

right now the soonest options after the PMTI Feb's are the May.

if their product is not released until March and the release of their product lapses the Feb calls and then i will roll the $15 calls into the April or May options.

JMHO

[mugur]

Cool, i'll look at the Feb options.
So you would not consider March calls or puts?

[nlightn]

yes...potential heating up here.

the only T/A factor i can see is if the price goes back down to fill the gap between $12.00 and $12.17...other than that it looks like clear sailing to me.

option wise...i'm holding the Feb $15 calls. price is a .40- .50 now.

PMTI announced that they would be presenting their product in the spring...that would mean March. so i figure that as we get closer to March that Feb call option will become valuable.

JMHO

[mugur]

I see the 50 MA crossed the other two moving averages , that's bullish, how about some option plays?

[nlightn]

great day !...price and volume up and held into the close.

chart is showing a new leg is ready to form.

[nlightn]

PM bid $12.18 ask $12.48...

somethings cooking.

volume was strong yesterday.

looking for volume of 135,000 and hold this price...

if so...

next leg moving to $15.

[nlightn]

needs volume of 135,000+ and a close at $11.57 or above.

it needs to hold that level of volume or exceed it and close at $11.57 or above...

that is the start of the next leg for PMTI.

until then it's in a range pattern.

[mugur]

still below $12?

[nlightn]

Palomar Medical Reports Financial Results for Third Quarter 2010
Palomar Medical Technologies (MM) (NASDAQ:PMTI)


Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of light-based systems for cosmetic treatments, today announced financial results for the third quarter ended September 30, 2010. Revenues for the quarter ended September 30, 2010 increased to $15.8 million, as compared to $14.5 million reported in the third quarter of 2009. Product and service revenues increased to $13.0 million, a 16 percent increase over the $11.2 million reported in the third quarter of 2009. Third quarter gross margin from product and service revenues was 60 percent, an increase over the 57 percent reported in the third quarter of 2009. Loss before income taxes for the third quarter ended September 30, 2010 was $2.0 million, which included a $1.5 million patent litigation expense and a $0.9 million non-cash stock-based compensation expense. Loss before income taxes for the third quarter ended September 30, 2009 was $0.2 million, which included a $100,000 patent litigation expense and a $1.0 million non-cash stock-based compensation expense. The Company reported net loss of $2.0 million, or $0.11 per share for the third quarter of 2010 and $0.3 million for the third quarter of 2009. The balance sheet continues to be strong with $102.8 million in cash, cash equivalents, short-term investments and marketable securities with no borrowings.

Chief Executive Officer Joseph P. Caruso commented, "Given the current economic climate, we are happy with the progress we are making, especially the trends experienced in the last few quarters. Our 23% increase in product revenues this quarter as compared to the same quarter last year is gratifying as this is the fourth consecutive quarter of growth and the largest percentage growth year over year in the last three years. Prices are stable and gross margins remain strong throughout the world. Our gross margin this quarter was a big improvement over the same time last year. Our efforts over the past two years to increase our international distribution are also paying off with 48% of total product and service revenues coming from outside North America. Our product portfolio and platform approach gives us the flexibility to adjust our business to meet the challenges in today's economy. Our sales and distribution network configure technology solutions to fit physicians' sites throughout the world in response to the particular economic pressure they are experiencing. We have also had great success with shifting our business model from principally one-time capital equipment sales to include recurring sources. This quarter, 41% of our revenue was generated from recurring sources."

Mr. Caruso continued, "We continue to invest in our consumer products initiative. Our branding and packaging are complete and we are building inventory to support a planned launch early next year. This is a new and exciting challenge for us representing a great opportunity to grow the business in the future."

Conference Call: As previously announced, Palomar will conduct a conference call and webcast today at 11:30 AM Eastern Time. Management will discuss financial results and strategic matters. If you would like to participate, please call [phone] or listen to the webcast in the About Palomar/Investors section of the Company's website at www.palomarmedical.com. A webcast replay will also be available.

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based cosmetic treatments have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the About Palomar/Investors section of the website.

With the exception of the historical information contained in this release, the matters described herein contain forward-looking statements, including, but not limited to, statements relating to new markets, future royalty amounts due from third parties, development and introduction of new products, and financial and operating projections. These forward-looking statements are neither promises nor guarantees, but involve risk and uncertainties that may individually or mutually impact the matters herein, and cause actual results, events and performance to differ materially from such forward-looking statements. These risk factors include, but are not limited to, results of future operations, technological difficulties in developing or introducing new products, the results of future research, lack of product demand and market acceptance for current and future products, the effect of economic conditions, challenges in managing joint ventures and research with third parties and government contracts, the impact of competitive products and pricing, governmental regulations with respect to medical devices, including whether FDA clearance will be obtained for future products and additional applications, the results of litigation, difficulties in collecting royalties, potential infringement of third-party intellectual property rights, factors affecting the Company's future income and resulting ability to utilize its NOLs, and/or other factors, which are detailed from time to time in the Company's SEC reports, including the report on Form 10-K for the year ended December 31, 2009 and the Company's quarterly reports on Form 10-Q. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Palomar Financial Summary:
Consolidated Statements of Operations (Unaudited)

Three Months Ended

September 30, Nine Months Ended

September 30,
2010 2009 2010 2009
Revenues:
Product revenues $9,273,158 $7,528,645 $27,655,391 $23,939,493
Service revenues 3,749,164 3,700,511 11,512,299 10,884,073
Royalty revenues 1,499,182 1,264,022 4,444,327 4,032,039
Funded product development revenues -- 806,482 -- 1,636,082
Other revenues 1,250,000 1,250,000 3,750,000 3,750,000
Total revenues 15,771,504 14,549,660 47,362,017 44,241,687

Costs and expenses:
Cost of product revenues 3,781,473 2,873,956 10,583,241 9,849,383
Cost of service revenues 1,367,316 1,901,303 4,320,439 5,417,280
Cost of royalty revenues 599,673 505,609 1,777,731 1,612,816
Research and development 3,545,622 3,305,311 11,320,691 10,125,279
Selling and marketing 4,663,632 4,062,930 14,408,442 13,464,732
General and administrative 4,267,535 2,451,496 11,579,566 7,566,053
Total costs and expenses 18,225,251 15,100,605 53,990,110 48,035,543

Loss from operations (2,453,747) (550,945) (6,628,093) (3,793,856)

Interest income 108,630 218,169 309,747 551,817
Other income 390,784 156,941 212,922 506,761

Loss before income taxes (1,954,333) (175,835) (6,105,424) (2,735,278)

Provision for (benefit from) income taxes 69,454 120,752 117,456 (780,319)

Net loss $(2,023,787) $(296,587) $(6,222,880) $(1,954,959)

Net loss per share:
Basic $(0.11) $(0.02) $(0.34) $(0.11)
Diluted $(0.11) $(0.02) $(0.34) $(0.11)

Weighted average shares outstanding:
Basic 18,561,877 18,065,655 18,539,847 18,058,246
Diluted 18,561,877 18,065,655 18,539,847 18,058,246


Consolidated Balance Sheets (Unaudited)

September 30,

2010 December 31,

2009
Assets
Current assets:
Cash and cash equivalents $76,623,685 $81,948,482
Short-term investments 1,999,675 25,000,000
Total cash, cash equivalents and short-term investments 78,623,360 106,948,482
Accounts receivable, net 5,035,232 4,436,219
Inventories 12,218,475 11,126,352
Other current assets 1,783,674 2,179,233
Total current assets 97,660,741 124,690,286

Marketable securities, at estimated fair value 24,129,348 4,024,313

Property and equipment, net 37,271,766 34,629,410

Other assets 218,716 126,087

Total assets $159,280,571 $163,470,096

Liabilities and Stockholders' Equity

Current Liabilities:
Accounts payable $3,326,847 $2,696,217
Accrued liabilities 9,245,816 8,959,679
Deferred revenue 3,793,124 5,221,924
Total current liabilities 16,365,787 16,877,820

Accrued income taxes 2,788,802 2,965,077

Total liabilities $19,154,589 $19,842,897

Stockholders' equity:
Preferred stock, $.01 par value--
Authorized - 1,500,000 shares
Issued -- none -- --
Common stock, $.01 par value--
Authorized - 45,000,000 shares
Issued – 18,573,262 and 18,521,045 shares, respectively 185,733 185,211
Additional paid-in capital 209,629,876 206,740,492
Accumulated other comprehensive loss (460,540) (292,297)
Accumulated deficit (69,229,087) (63,006,207)
Total stockholders' equity $140,125,982 $143,627,199

Total liabilities and stockholders' equity $159,280,571 $163,470,096
CONTACT: Palomar Medical Technologies, Inc.
Kerry McAnistan, Investor Relations Assistant
781-993-2411
[e-mail]

[nlightn]

PTMI CHART

sitting right at the 38.2% FIB and resting between the 100MA and 200MA....

new leg up ?

needs 135,000 in volume and move past $11 and beyond on volume.

[nlightn]

well i never left. in fact i'm increasing my position as this adjustment in price is shaking out weak hands or the shorts.

also in the Feb 15calls. if needed i'll roll them.

GLTY

[mugur]

Time to get back in?

[nlightn]

The Dr. Oz Show Features Palomar(R) Medical's SlimLipo(TM) Body Sculpting Laser
GlobeNewsWire.com
March 17, 2010


Palomar Medical Technologies, Inc. (Nasdaq:PMTI), a leading researcher and developer of lasers and pulsed-light systems for aesthetic treatments, is pleased to announce that the Palomar SlimLipo body sculpting laser will be featured on The Dr. Oz Show on Wednesday, March 17.

Kenneth Rothaus, MD, a board-certified plastic surgeon in New York City and an early clinical user of the SlimLipo laser, will present SlimLipo during the "Age Erasers!" segment of Wednesday's show. Dr. Rothaus will discuss with Dr. Oz how a laser-based enhancement to liposuction can help patients look and feel better by "melting" unwanted fat (lipolysis) and tightening skin through soft tissue coagulation – offering patients a more desirable, youthful look.

Dr. Rothaus remarks, "SlimLipo has transformed my liposuction practice. My patients are demanding these types of procedures. Since there's virtually no bruising or post-procedure pain, these patients are often back to work the same day."

Drs. Oz and Rothaus will be joined by a guest female patient who, having had a SlimLipo treatment by Dr. Rothaus just one week ago, will reveal her impressive result. Drs. Oz and Rothaus will then demonstrate the SlimLipo laser in the studio, showing how quickly it melts fat.

To find out what time and channel The Dr. Oz Show is on in your area, please visit www.doctoroz.com/find-station.

If you are a prospective patient who may be interested in laser-assisted liposuction procedures, please visit www.lifesculpt.com to learn more about the LifeSculpt™ procedure and find a local physician. Physicians who want to learn more about the SlimLipo body sculpting laser for laser-assisted lipolysis, including the latest clinical data and before-and-after photos, should visit www.slimlipo.com.

About Palomar Medical Technologies, Inc.: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based hair removal have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

For more information on Palomar and its products, visit Palomar's website at www.palomarmedical.com. To continue receiving the most up-to-date information and latest news on Palomar as it happens, sign up to receive automatic e-mail alerts by going to the Investor Relations section of the website.

CONTACT: Palomar Medical Technologies, Inc.

Press Contact:

Branden Morris

[phone]

[e-mail]

[nlightn]

Stocks Looking Good To End The Year Ahead
indieresearch.com
Sept. 24, 2010


After the market broke back on Monday, stocks took a three-day slumber, but just as doubt started to set in on the sustainability of the near-term rally, stocks exploded to the upside to close out the week. The economic data continues to come in fairly mixed, but the strong manufacturing report (ex-transportation) along with a few solid earnings reports was enough for investors today. Given attractive valuations across many sectors, we continue to believe that slow, steady growth is enough to help stocks end the year higher from here.

The Cosmetic Laser Stocks Index was the top performing tickerspy Index on the day, led by Palomar Medical Technologies (Nasdaq: PMTI - News) with a 8% gain.

Stocks soared on the day, led by a 54-point, or 2.3% increase, in the Nasdaq. The Dow jumped 198 points, while the S&P leapfrogged 24 points to 1,149. Oil rose $1.31 to $76.49 a barrel, while gold added $1.70 to $1,296.00 an ounce.

On the economic front, August new home sales were unchanged from July at an annual rate of 288,000, according to the Commerce Department. Economists had expected an increase to a rate of 295,000. Durable goods orders declined by -1.3% in August, compared to the -1.0% analyst expectations. However, excluding the volatile transportation sector, orders increased by 2%, or twice the consensus estimate.

In earnings news, footwear and apparel firm Nike (NYSE: NKE - News) gained 2.5% after posting better-than-expected fiscal first-quarter earnings. The company earned $559 million, or $1.19 per share, compared to $513 million, or $1.04 per share, in the same period last year. Sales rose by 8% to $5.18 billion. Analysts were looking for $1.01 in EPS on $5.22 billion in sales. At the end of the second quarter, 61 Pros counted Nike among their top-15 U.S.-listed equity positions, and 405 tickerspy members hold the stock in their portfolios.

Athletic shoe retailer Finish Line (Nasdaq: FINL - News) slipped by -9.2% after missing EPS consensus in the fiscal second quarter. The company recorded net income of $16.8 million, or 31 cents per share, in the three months ended August 28th, compared to a net loss of -$874,000, or -2 cents per share, a year ago. The profit per share came in -5 cents below Wall Street's expectations. Revenue increased by 1% to $301.1 million.

Business software firm Tibco Software (Nasdaq: TIBX - News) spiked by 12.6% after reporting its third-quarter results. The company posted profits of $17.4 million, or 10 cents per share, compared to $14.9 million, or 9 cents per share, in the year-ago period. Excluding certain items, adjusted EPS came to 17 cents, besting the analyst consensus by 2 cents. Revenues were up 23% for the quarter to $184.5 million.

Homebuilder KB Home (NYSE: KBH - News) gained 3.4% after announcing a narrowed loss for the third quarter ended August 31st. The company's net loss totaled -$1.4 million, or -2 cents per share, compared to -$66 million, or -87 cents per share, in the same period last year. Revenue was up by 9% to $501.0 million. Analysts were looking for a -15 cent loss per share on $477.8 million in revenue. Two Pros counted KB Homes among their top-15 U.S.-listed equity positions at the end of the second quarter, and 143 tickerspy members currently hold the stock in their portfolios.

Fun and informative, tickerspy.com is a free investing website where you can track multiple stock portfolios and compare against 250 proprietary Indexes tracking themes from dividends to ETFs to green energy to precious metals. Best of all, tickerspy.com lets you spy on the portfolios of nearly 3,000 Wall Street institutions and hedge funds and see graphs of their performance. Try tickerspy.com today and find out how you stack up against investing legends like Warren Buffett!

http://finance.yahoo.com/news/Stocks-Looking-Good-To-End-indie-1391846209.html?x=0&.v=1

[nlightn]

Palomar to Launch Home Use Laser by Spring 2011
September 21, 2010



BURLINGTON, Mass., Sept. 21, 2010 (GLOBE NEWSWIRE) -- Palomar Medical Technologies Inc. (Nasdaq:PMTI - News), a leading researcher and developer of light-based systems for cosmetic treatments, today announced that it would move the launch of its patented, home use laser for the treatment of periorbital wrinkles by a few months. This is the only laser with over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for the treatment of periorbital wrinkles. OTC clearance allows the laser to be marketed and sold directly to consumers without a prescription.

Palomar Chief Executive Officer Joseph P. Caruso said, "The change in the timing of our launch is related to the use of lotion with the laser. The laser is in production, and we are building inventory for the launch. The branding and product positioning are complete and deliver a powerful message. We have distribution partners in place and we will take advantage of the additional time to further prepare our marketing, public relations, and communication plans in support of the spring launch."

In clinical studies, hundreds of participants used this home-use laser in thousands of treatments and were very pleased with the results. A panel of physicians saw a noticeable reduction in wrinkles in 92% of participants after 4 weeks, and 84% of participants agreed that it appears to eliminate their fine lines after 12 weeks.

Mr. Caruso continued, "Entering the consumer market has been one of Palomar's growth strategies for over a decade. Introducing a home-use laser will increase awareness among a much broader base of consumers about the benefits of laser treatment for skin care, engage more people by making laser cosmetic treatments a part of their daily routine, and help to establish periodic laser treatments as an essential element of a new standard of skin care. In addition to opening up the very large, untapped consumer market, we believe the increased awareness will lead to increased interest in professional treatments. This is a revolutionary product which we believe will have a meaningful impact on how people treat their aging skin."

About Palomar Medical Technologies Inc: Palomar is a leading researcher and developer of light-based systems for cosmetic treatments. Palomar pioneered the optical hair removal field, when, in 1997, it introduced the first high-powered laser hair removal system. Since then, many of the major advances in light-based cosmetic treatments have been based on Palomar technology. In December 2006, Palomar became the first company to receive a 510(k) over-the-counter (OTC) clearance from the United States Food and Drug Administration (FDA) for a new, patented, home-use, light-based hair removal device. In June 2009, Palomar became the first company to receive a 510(k) OTC clearance from the FDA for a new, patented, home-use, laser device for the treatment of periorbital wrinkles. OTC clearance allows the product to be marketed and sold directly to consumers without a prescription. There are now millions of light-based cosmetic procedures performed around the world every year in physician offices, clinics, spas and salons. Palomar is testing many new and exciting applications to further advance the hair removal market and other cosmetic applications. Palomar is focused on developing proprietary light-based technology for introduction to the mass markets.

Contact:

Palomar Medical Technologies, Inc.
Kerry McAnistan, Investor Relations Assistant
781-993-2411
[e-mail]

http://finance.yahoo.com/news/Palomar-to-Launch-Home-Use-pz-303218305.html?x=0&.v=1

[nlightn]

Coverage initiated on Palomar Medical by JMP Securities
Briefing.com
Sep 15, 2010


http://finance.yahoo.com/q/ud?s=PMTI

[nlightn]

Waiting For A Rebound
Investopedia
Sept. 3, 2010

I have seen it written that you cannot put a price on beauty. The performance of stocks in the aesthetics sector would seem to suggest otherwise. As the housing bubble exploded, the economy fell into recession, credit suddenly became tight, and people stopped finding the money to pay for all manner of personal exterior renovations.

If it is true that whatever goes up must come down, can it also be true that a sector laid low by a punishing reduction in disposable income and easy credit could rebound again? Since people do not really change all that quickly, it seems reasonable to assume that the demand for cosmetic procedures is still out there and that when disposable income rebounds, so too will this sector.

Allergan

Allergan (NYSE:AGN) does have a sizable eye-care business, but aesthetic and cosmetic procedures are a large part of the story. Allergan not only has its well-known Botox franchise, but dermal fillers, an obesity product (the Lap-Band) and a silicone breast implant business as well.

Medicis

Like Allergan, Medicis (NYSE:MRX) is something of a hybrid between a pharmaceutical company and an aesthetics company. Medicis has a sizable franchise in acne-related dermatological products (which are not generally thought of as aesthetic), but is looking to augment this with products like Dysport (a rival to Botox) and the Liposonix ultrasound system for body sculpting.

Lasers, Ultrasound And Heat ... Oh My!

In addition to the two large quasi-pharmaceutical companies, there are a host of companies that market systems that use laser, ultrasound, or thermal energy to rejuvenate skin, remove hair, eliminate scars and tattoos, or reduce cellulite.

Palomar Medical Technologies (Nasdaq:PMTI) is a leader in the light-based approaches to aesthetics. On top of very competitive products, Palomar owns a valuable IP estate and has managed to force many of its rivals to license those patents. With the launch of the Aspire system in 2009, Palomar is getting more involved in the body sculpting market and introducing a consumables component to its business model.

Israel's Syneron (Nasdaq:ELOS) was once a stock market darling, but those days are long past as revenue as fallen by more than half from its peak in 2007. Syneron pioneered technology that combines RF energy and optical energy into products that offered both better results and more comfort to the patient. Since then, the company has acquired one-time competitor Candela to add to its laser-based technologies and products.

Solta Medical (Nasdaq:SLTM) brings something a little different to the game. Solta offers three different laser-based platforms, but builds them with disposable treatment tips. That may seem like only a minor engineering detail, but these high-margin consumables give the company a direct stake in the procedure volumes as well as more flexibility in marketing its units (Solta can participate in the common practice of all but giving away units in exchange for higher tip prices). Of course, it certainly does not hurt that Solta boasts of shorter treatment times for its users as well as more enduring benefits.

The Prettiest Pick

With the whole sector in the doldrums, it is probably not surprising that there are more than a few bargains to be found here. Solta seems to be getting a market value that suggests a lot of investors either have completely forgotten about the company or expect it not to survive this downturn. Palomar is likewise not afforded the sort of multiples you might expect from an industry leader - Palomar's current enterprise value is just $65 million, even though the company has a clean balance sheet and credible prospects to return to profitability and free cash flow generation.

Allergan and Medicis do not offer nearly the same discounted valuation as the "laser companies", mostly because the businesses are more diversified and have continued to grow through the recession (while Palomar's revenue run-rate is half of its peak level). Both are fine companies, but not really cheap enough to be rebound stocks or value picks.

The Bottom Line
Aesthetics is a volatile and intensely competitive sector. It also happens to be quite lucrative during the good times and the right combination of company, technology and timing can produce winning stocks. There is still time for due diligence here, and risk-tolerant investors may want to consider making a play on the idea that vanity can still pay.

Use the Investopedia Stock Simulator to trade the stocks mentioned in this stock analysis, risk free!

By Stephen Simpson

Stephen Simpson, CFA, is a freelance financial writer, investor, and consultant. He has worked as an equity analyst for both sell-side and buy-side investment companies in both equities and fixed income. Stephen's consulting work has focused primarily upon the healthcare sector, while he has also written extensively for publication on topics pertaining to investments, security analysis, and healthcare. Simpson operates the Kratisto Investing blog, and can be reached there.

[GreekPimp]

PMTI finally moved to their new location on Network Drive in Burlington, MA

[spec machine]

I think you got that call right.

[GreekPimp]

yea, i dont own any shares of this company and honestly have no real interest. just looking into it for my grandmother to see if her stocks are worth anything. Hope everyone here does well.

ill see what i can do about getting some pictures of the old and new place and posting them for you guys. something to add to the iBox